Session » Posters: Clinical and Therapeutic Aspects I

Date: Thursday, March 19, 2026

Time: 6:00PM-7:00PM

Meeting: 2026 Pediatric Rheumatology Symposium

6:00PM-7:00PM: Abstract Number: 006

Age Matters: Clinical Profile and IVIG Responsiveness in infants with Kawasaki Disease. A multicentric retrospective analysis of 36 patients from North India

6:00PM-7:00PM: Abstract Number: 040

Antiphospholipid Antibody-Mediated Disease: Clinical Characteristics and Outcomes of Catastrophic Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia in a Single Center Pediatric Cohort

6:00PM-7:00PM: Abstract Number: 028

Are You Positive About this Positive ANA Referral? Outcomes for ANA Based Referrals to Pediatric Rheumatology and Subsequent Disease Development

6:00PM-7:00PM: Abstract Number: 038

Assessment of Disease Activity and Skeletal Damage in Pediatric Chronic Nonbacterial Osteomyelitis and the Effects of Different Treatment Regimens

6:00PM-7:00PM: Abstract Number: 047

Association of anti-DFS70 with autoimmune diseases in children

6:00PM-7:00PM: Abstract Number: 008

Body Mass Index, Neighborhood Opportunity, and Outcomes of Childhood-Onset Lupus

6:00PM-7:00PM: Abstract Number: 014

Bone Microarchitecture Impairment in Juvenile Systemic Lupus Erythematosus Patients: A Comparative Study

6:00PM-7:00PM: Abstract Number: 020

Building Consensus on Key Research Domains and Research Topics in Childhood-onset Neuropsychiatric Lupus: An International Prioritization Initiative

6:00PM-7:00PM: Abstract Number: 052

Case Series: Treatment of Refractory Lung Disease in Systemic Juvenile Idiopathic Arthritis with Cyclophosphamide and Rituximab Combination Therapy

6:00PM-7:00PM: Abstract Number: 043

Challenges of Cognitive Screening and Formal Neuropsychological Evaluation in Youth with Childhood-Onset Systemic Lupus Erythematosus: A Survey of CARRA Providers

6:00PM-7:00PM: Abstract Number: 031

Clinical Characteristics and Diagnostic Predictors of Inflammatory Bowel Disease in Patients with Chronic Nonbacterial Osteomyelitis – A Single Center Retrospective Analysis

6:00PM-7:00PM: Abstract Number: 048

Clinical characteristics of childhood-onset primary Sjögren’s syndrome in South Korea: two centers’ experiences

6:00PM-7:00PM: Abstract Number: 051

Do Changes in the Weather Influence Joint Pain and Stiffness in Children with Juvenile Idiopathic Arthritis?

6:00PM-7:00PM: Abstract Number: 044

Efficacy of Rituximab Biosimilars in Pediatric ANCA-Associated Vasculitis

6:00PM-7:00PM: Abstract Number: 009

Functional Lumen Imaging Probe (FLIP) for the Assessment of Esophageal Involvement in Juvenile Systemic Sclerosis: Characteristics and Clinical Utility

6:00PM-7:00PM: Abstract Number: 045

Genotypes and Clinical Phenotypes of Monogenic Autoinflammatory Disorders in Michigan

6:00PM-7:00PM: Abstract Number: 036

Giant Aneurysms in Kawasaki Disease: A Large Quarternary Single Center Experience

6:00PM-7:00PM: Abstract Number: 013

Kikuchi-Fujimoto’s Disease in Systemic Lupus Erythematosus: Single-center Experience

6:00PM-7:00PM: Abstract Number: 025

Longitudinal Single Cell Transcriptomic Analysis of Type I and II Interferon (IFN) Response Genes (IRG) in Refractory Juvenile Dermatomyositis (JDM) Patients with Baricitinib Treatment

6:00PM-7:00PM: Abstract Number: 011

Lung Transplant for Pediatric Dermatomyositis Patients with Interstitial Lung Disease: A Single-Center Experience

6:00PM-7:00PM: Abstract Number: 005

Magnetic Resonance Enterography Detected Sacroiliitis in Pediatric Crohn’s Disease: A Retrospective Cohort Study

6:00PM-7:00PM: Abstract Number: 022

Mental Health concerns in Patients with Juvenile Idiopathic Arthritis and Their Caregivers: A Systematic Review

6:00PM-7:00PM: Abstract Number: 032

Methotrexate Response in Systemic JIA: Real-World Evidence from a Tertiary-Care Cohort

6:00PM-7:00PM: Abstract Number: 049

Novel Insights of Brain MRI Features in Neonatal Lupus Erythematosus with Hydrocephalus

6:00PM-7:00PM: Abstract Number: 015

Obinutuzumab Induces Histologic Remission And Deep Kidney Parenchymal B-Cell Depletion In Patients With Lupus Nephritis: Exploratory Analyses From The REGENCY Trial

6:00PM-7:00PM: Abstract Number: 037

Off-the-Shelf Anti-CD19 CAR T-cell Therapy with Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment

6:00PM-7:00PM: Abstract Number: 029

Oral vs Subcutaneous Methotrexate at High Dose for Pediatric Anterior Uveitis

6:00PM-7:00PM: Abstract Number: 041

Pediatric Behçet’s Disease: A 13-Year Single-Center Experience Highlighting Diagnostic Delays and High Neurological Burden

6:00PM-7:00PM: Abstract Number: 034

Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Management Across Countries: A Survey to Inform Future Comparative Effectiveness Research

6:00PM-7:00PM: Abstract Number: 023

Screening Tools for Spondyloarthropathies among Patients with Inflammatory Bowel Disease: A Scoping Review

6:00PM-7:00PM: Abstract Number: 039

Single-center Experience of Voclosporin Use for Pediatric Lupus Nephritis

6:00PM-7:00PM: Abstract Number: 016

Still’s Disease Associated Lung Disease: Experience from a Tertiary Italian Centre

6:00PM-7:00PM: Abstract Number: 007

Subtle Signs, Severe Consequences: Clinical profile of infants with giant coronary aneurysms compared to those with normal coronaries. A multicentric retrospective analysis of infants with Kawasaki disease

6:00PM-7:00PM: Abstract Number: 050

The Quiet Beginning: Early Pediatric Systemic Lupus Erythematosus (SLE) Without Nephritis and the Path to Renal Involvement

6:00PM-7:00PM: Abstract Number: 024

Therapeutic Plasma Exchange in Pediatric Autoimmune Encephalitis

6:00PM-7:00PM: Abstract Number: 026

Treatment strategies for articular flares in JIA patients receiving biologic therapy

« View all sessions from this meeting

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].